Vowst denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vowst are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Blue Cross Blue Shield Denied Vowst as Non-Formulary

Vowst (fecal microbiota, live-jslm) is a newer FDA-approved biotherapeutic that many BCBS plans have not yet placed on the standard drug formulary, or have placed on an exclusion list. A non-formulary denial means the plan will not pay at any standard cost-sharing tier because the drug is not on the covered drug list.

Non-formulary status does not mean the drug is medically unnecessary — it means the plan hasn't included it in its standard coverage structure. Formulary exception requests and medical-necessity appeals are designed precisely for this situation.

## Why This Denial Is Appealable

• Formulary exception / medical-necessity override: Most BCBS plans allow a physician to request a formulary exception when no formulary alternative is clinically appropriate for the patient. This is a distinct pathway from the standard PA process and can result in coverage at a non-preferred tier.
• ACA §2719 external review: After an internal denial of a formulary exception request, you may request independent external review. The external reviewer evaluates whether BCBS's denial was consistent with clinical evidence. File within approximately four months of the internal denial.
• ERISA §503 (employer plans): Requires BCBS to disclose all criteria and the basis for denying the formulary exception.
• Expedited review: Available if delay creates an urgent clinical risk.

## Key Argument for Non-Formulary Appeals

The strongest non-formulary appeal demonstrates that every formulary alternative is clinically inappropriate for this specific patient — not just less preferred, but genuinely unsuitable. For Vowst, you would need to show that BCBS's formulary alternatives for C. diff prevention are either not indicated for this patient's situation, were tried and failed, or are not equivalent (e.g., because Vowst is the sole FDA-approved product in its specific class for this indication).

## Documentation to Gather

• BCBS formulary: Obtain the current formulary and identify every alternative BCBS considers an equivalent option. Your appeal must address each one.
• Prescriber medical-necessity and formulary-exception letter: The physician must address each formulary alternative by name, explain why it is not appropriate for this patient, and document why Vowst is medically necessary.
• C. diff recurrence history: Lab-confirmed episodes, prior antibiotic treatment, and outcomes — establishing the clinical context.
• Prior treatment trials (if any): If any formulary alternatives were already tried, document those trials with dates and outcomes.
• FDA prescribing label for Vowst: Confirms the approved indication and distinguishes Vowst from alternatives that may not share the same regulatory standing.

## Criteria-Mapping Approach

| BCBS formulary alternative | Why not appropriate for this patient | |---|---| | [Alternative A] | Not FDA-approved for same indication / tried and failed / contraindicated per prescriber | | [Alternative B] | Same analysis |

## Next Step

Submit a formulary exception request through BCBS's standard PA portal with the documentation above. If denied, file a written internal appeal and then external review. The manufacturer's patient-assistance program may also help bridge coverage during the appeals process.